GUANGZHOU, China, Nov. 15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into a development and
commercialization agreement with Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad”) which will bring myChoice tumor testing for homologous recombination deficiency, or HRD, to China.

The Myriad myChoice CDx